Project Details
Description
The overall goal of this project is to perform preclinical and phase II clinical testing of a Th17-induced pulsed dendritic cell vaccine to assess its efficacy in preventing relapse of high grade ovarian cancer in first remission after debulking surgery and platinum-based adjuvant or neoadjuvant chemotherapy.
| Status | Finished |
|---|---|
| Effective start/end date | 9/1/23 → 8/31/26 |
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.